Author

Everardo Macias

Duke UniversityORCID 0000-0002-2846-4451Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Andrew J Armstrong· 1 shared Antonina MitrofanovaiD· 1 shared David Harold DrewryiD· 1 shared Emily Cordova· 1 shared Ikeer Y. Mancera-OrtiziD· 1 shared Jasmine PlummeriD· 1 shared Jiaoti HuangiD· 1 shared Jung Wook ParkiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew J Armstrong

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer

Umar Mehraj, Uran Maimekov, Shaista Manzoor, Emily Cordova, Manasiben Patel, Ikeer Y. Mancera-Ortiz, Stefanie Howell, Zachary W. Davis‐Gilbert, Mu‐En Wang, Ming Chen, Jung Wook Park, Yuzhuo Z. Wang, Jasmine Plummer, Andrew J Armstrong, Jiaoti Huang, , Everardo Macias

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

bioRxiv · Nov 12, 2025 · PreprintCancer Biology